These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 28851502)

  • 1. Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents.
    Beretta GL; Cassinelli G; Pennati M; Zuco V; Gatti L
    Eur J Med Chem; 2017 Dec; 142():271-289. PubMed ID: 28851502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
    Hegedus C; Ozvegy-Laczka C; Apáti A; Magócsi M; Német K; Orfi L; Kéri G; Katona M; Takáts Z; Váradi A; Szakács G; Sarkadi B
    Br J Pharmacol; 2009 Oct; 158(4):1153-64. PubMed ID: 19785662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
    Dohse M; Scharenberg C; Shukla S; Robey RW; Volkmann T; Deeken JF; Brendel C; Ambudkar SV; Neubauer A; Bates SE
    Drug Metab Dispos; 2010 Aug; 38(8):1371-80. PubMed ID: 20423956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?
    Brózik A; Hegedüs C; Erdei Z; Hegedus T; Özvegy-Laczka C; Szakács G; Sarkadi B
    Expert Opin Drug Metab Toxicol; 2011 May; 7(5):623-42. PubMed ID: 21410427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
    Pick A; Wiese M
    ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of tyrosine kinase inhibitors with the MDR- related ABC transporter proteins.
    Wang XK; Fu LW
    Curr Drug Metab; 2010 Sep; 11(7):618-28. PubMed ID: 20812904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.
    Deng J; Shao J; Markowitz JS; An G
    Pharm Res; 2014 Sep; 31(9):2237-55. PubMed ID: 24842659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.
    D'Cunha R; Bae S; Murry DJ; An G
    Biopharm Drug Dispos; 2016 Oct; 37(7):397-408. PubMed ID: 27418107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
    Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells.
    Wu S; Fu L
    Mol Cancer; 2018 Feb; 17(1):25. PubMed ID: 29455646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration.
    Krchniakova M; Skoda J; Neradil J; Chlapek P; Veselska R
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32365759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversing multidrug resistance by tyrosine kinase inhibitors.
    He M; Wei MJ
    Chin J Cancer; 2012 Mar; 31(3):126-33. PubMed ID: 22237041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro.
    Cihalova D; Staud F; Ceckova M
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):105-16. PubMed ID: 25986678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: a new mechanism of beverage-drug interaction.
    Fleisher B; Unum J; Shao J; An G
    J Pharm Sci; 2015 Jan; 104(1):266-75. PubMed ID: 25418056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters.
    Ozvegy-Laczka C; Cserepes J; Elkind NB; Sarkadi B
    Drug Resist Updat; 2005; 8(1-2):15-26. PubMed ID: 15939339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
    Erdem L; Giovannetti E; Leon LG; Honeywell R; Peters GJ
    Curr Top Med Chem; 2012; 12(15):1649-59. PubMed ID: 22978339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.
    Azzariti A; Porcelli L; Simone GM; Quatrale AE; Colabufo NA; Berardi F; Perrone R; Zucchetti M; D'Incalci M; Xu JM; Paradiso A
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):335-46. PubMed ID: 19495754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia.
    Polillo M; Galimberti S; Baratè C; Petrini M; Danesi R; Di Paolo A
    Int J Mol Sci; 2015 Sep; 16(9):22811-29. PubMed ID: 26402671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.